The effects of elexacaftor/tezacaftor/ivacaftor beyond the epithelium: spurring macrophages to fight infections

Elexacaftor/tezacaftor/ivacaftor (ETI) is a modulator therapy recently approved for patients with cystic fibrosis (CF) with at least one F508del mutation. The resulting impact on the health of CF patients has been tremendous, improving many clinical aspects ( e.g. sweat chloride, lung function and reduction in pulmonary exacerbation) of this complex disease, and enhancing patients’ quality of life [1]. Elexacaftor/tezacaftor/ivacaftor treatment improves the antimicrobial function of monocytes/macrophages http://bit.ly/3ZvIsxZ